SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, according to a large study. Results showed a 20% to 30% lower risk for these conditions,

New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.

A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 diabetes.

Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By encouraging the kidneys to eliminate sugar from the body through urine, they reduce blood sugar.